AHAnne-Renee Hartman

Anne-Renee Hartman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne-Renee Hartman has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma

    by Raphael Bueno, Elisha Hughes, Susanne Wagner, Alexander S. Gutin, Jerry S. Lanchbury, Yifan Zheng, Michael A. Archer, Corinne Gustafson, Joshua T. Jones, Kristen Rushton, et al.


  • Open Access

    Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer

    by Anne‐Renee Hartman, Rajesh R. Kaldate, Lisa M. Sailer, Lisa Painter, Charles E. Grier, Robbin R. Endsley, Marlena Griffin, Stephanie A. Hamilton, Cynthia A. Frye, Mark A. Silberman, et al.

    BACKGROUND: This study assessed BRCA1 and BRCA2 mutation prevalence in an unselected cohort of patients with triple‐negative breast cancer (BC).METHODS: One hundred ninety‐nine patients were enrolled. Triple negativity was defined as neu not overexpressed by fluorescence in situ hybridization. Having given consent, patients had BRCA1 and BRCA2 full sequencing and large rearrangement analysis. Mutation prevalence was assessed among the triple‐negative BC patients and the subset of patients without a family history of breast/ovarian cancer. Independent pathological review was completed on 50 patients.RESULTS: Twenty‐one deleterious BRCA mutations were identified—13 in BRCA1 and 8 in BRCA2 (prevalence, 10.6%). In 153 patients (76.9%) without significant family history (first‐degree or second‐degree relatives with BC aged P = .0005) than expected based on previously established prevalence tables among patients unselected for pathology. BRCA1 mutation prevalence was lower, and BRCA2 mutation prevalence was higher, than previously described. Additional mutation carriers would have met new NCCN testing guidelines, underscoring the value of the updated criteria. Study data suggest that by increasing the age limit to 65 years, all carriers would have been identified. Cancer 2011;. © 2011 American Cancer Society.